Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions

Exclusion Criteria

• •Scatter laser photocoagulation or macular photocoagulation within 3 months of study entry in the study eye
• •Intraocular surgery in the study eye within 3 months of study entry
• •Use of intraocular or periocular injection of steroids in the study eye (e.g., triamcinolone) within 4 months of study entry
• •Previous use of an anti-VEGF drug within 3 months of study entry
• •Cataract surgery in the study eye within 3 months of study entry; Yttrium-Aluminum-Garnet (YAG) laser capsulotomy within 1 month of study entry; or any other intraocular surgery within 3 months preceding Day 0.
• •History of vitreoretinal surgery in the study eye within 3 months of study entry
• •Uncontrolled glaucoma (defined as intraocular pressure ³30 mm Hg despite treatment with anti-glaucoma medications)
• •History of cerebral vascular accident, myocardial infarction, transient ischemic attacks within 3 months of study enrollment.
• •Pregnancy (positive pregnancy test) or lactation
• •Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.
• •Have the presence of active malignancy, including lymphoproliferative disorders. Subjects with a history of fully resolved basal or squamous cell skin cancer may be enrolled.
• •Any condition that the investigator believes would pose a significant hazard to the subject if investigational therapy were initiated.
• •History of allergy to humanized antibodies or any component of the ranibizumab formulation
• •Inability to comply with study or followup procedures
• •Participation in another simultaneous medical investigation or trial